SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · AstraZeneca reported H1 2026 Total Revenue of $30.7B (+6% CER) and Core…

ASTRAZENECA PLC · 6-K filed Jul 27, 2026 at 07:51 ET

At the news

MIXEDIMPACT 6/10

6-K filed Jul 27, 2026 at 07:51 ET

AstraZeneca reported H1 2026 Total Revenue of $30.7B (+6% CER) and Core EPS of $5.21 (+11% CER), with strong double-digit growth in Oncology and Rare Disease offset by BioPharmaceuticals headwinds from Farxiga US loss of exclusivity and China VBP. Q2 2026 Reported EPS was essentially flat (+2% actual, -2% CER) as R&D and SG&A spending increased. The company reconfirmed FY 2026 guidance (mid-to-high single-digit revenue growth, low double-digit Core EPS growth) and announced two license deals (Dizal $600M upfront, Sino Biopharma $200M upfront), but the Wainua CARDIO-TTRansform Phase III failure in ATTR-CM is a notable pipeline setback.

  • Total Revenue H1 2026: $30,672M (+9% actual, +6% CER); Q2: $15,384M (+6% actual, +5% CER)
  • Reported EPS H1: $3.60 (+4% actual, +3% CER); Q2: $1.61 (+2% actual, -2% CER)
  • Core EPS H1: $5.21 (+12% actual, +11% CER); Q2: $2.63 (+21% actual, +18% CER)
  • Oncology Product Revenue H1: $14,123M (+18% actual, +15% CER); Rare Disease: $4,911M (+13% actual, +11% CER)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access